Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen

DB10076ApprovedVaccinesInactivated Haemophilus Influenzae B Vaccine

Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is a vaccine for intramuscular injection used in the prevention of invasive disease caused by Haemophilus influenzae type... H. influenzae is a Gram-negative coccobacillus that can cause infections including sepsis and meningitis.

First approval
Canada, 2000 · United States, 1993
Also known as
Haemophilus influenzae type B strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Brand names
  • Acthib
  • Pentacel

Resolves to

Compound
UNIIFLV5I5W26R
Clinical / RWD
RxNorm1300464

What you can answer from here — as of September 30, 2025

53Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
16Marketed productsAcross 4 countries and 8 labellers
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which other approved drugs treat the same conditions as Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In